
Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery
GENERAL SUMMARY
This Executive Director position will report to the Senior Vice President, Research & Early-Stage Product Development and lead a team of translational scientists and drug development experts tasked with bringing innovative gene therapies to patients. The incumbent will have a high level of passion for 4DMT’s mission and the ability to operate as an effective strategic and tactical thinker. They will also be effective as a hands-on manager and supervisor of individual work. Candidates should have a PhD or MD/PhD degree (or equivalent) in Biological Sciences or a related discipline, with significant experience in pharmaceutical research and development. They will lead a preclinical and translational group responsible for: (1) developing target-engagement biomarkers and clinical biomarkers with relevance to Proof of Concept (POC) gene therapy studies, (2) conducting laboratory and in silico analyses of biomarker readouts generated in the relevant Phase 1 and Phase 2 gene therapy studies, (3) performing immunological assays and analyses relevant to detecting host immune responses to 4DMT gene therapy vectors in the clinical trial setting, and (4) overseeing outsourced performance of preclinical pharmacology and toxicology studies of 4DMT gene therapy vectors, in partnership with external CROs. This role will interact and collaborate with multiple functions at 4DMT, including but not limited to Clinical Science and Operations, Regulatory Affairs, Discovery & Innovation, Commercial, and CMC.
MAJOR DUTIES & RESPONSIBILITIES:
QUALIFICATIONS:
Education:
Experience:
Skills:
Travel: 5-10%
Physical Requirements and Working Conditions:
Base salary compensation range: $270,000 - 342,000
Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.
4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.
Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations.
We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together:
- Dare to Cure
- Break Boundaries
- Beyond Yourself
- Prepare & Execute Relentlessly
Join us in creating the future of genetic medicine.